Metastatic gastrointestinal stromal tumors

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue SUPPL. 1, 2011, Pages

  Aubin, Francine ^a   Blanke, Charles D ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLACEBO; STEM CELL FACTOR; SUNITINIB;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CARCINOGENESIS; CARDIOTOXICITY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LETHARGY; LOW DRUG DOSE; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; OVERALL SURVIVAL; PERIORBITAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; SALVAGE THERAPY; SKIN DISCOLORATION; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; SALVAGE THERAPY;

EID: 79151475060     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1512-9     Document Type: Article

References (39)

1. K Sircar BR Hewlett JD Huizinga, et al. 1999 Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors Am J Surg Pathol 23 377 389 1:STN:280:DyaK1M3htlGmuw%3D%3D 10.1097/00000478-199904000-00002 10199467
2. S Hirota K Isozaki Y Moriyama, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 1:CAS:528:DyaK1cXotVyhsw%3D%3D 10.1126/science.279.5350.577 9438854
3. Y Yarden W-J Kuang T Yang-Feng, et al. 1987 Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand EMBO J 6 3341 3351 1:CAS:528:DyaL1cXhtVOhtLs%3D 2448137
4. BP Rubin S Singer C Tsao, et al. 2001 KIT activation is a ubiquitous feature of gastrointestinal stromal tumors Cancer Res 61 8118 8121 1:CAS:528:DC%2BD3MXovVShs7w%3D 11719439
5. MC Heinrich CL Corless GD Demetri, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 4342 4349 1:CAS:528:DC%2BD2cXpsVWqu7Y%3D 10.1200/JCO.2003.04.190 14645423
6. M Debiec-Rychter R Sciot A Le Cesne, et al. 2006 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 1093 1103 1:CAS:528:DC%2BD28Xks1ertb0%3D 10.1016/j.ejca.2006.01.030 16624552
7. MC Heinrich K Owzar CL Corless, et al. 2008 Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group J Clin Oncol 26 5360 5367 1:CAS:528:DC%2BD1MXhslCmug%3D%3D 10.1200/JCO.2008.17. 4284 18955451
8. MC Heinrich CL Corless A Duensing, et al. 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710 1:CAS:528:DC%2BD3sXntFWitQ%3D%3D 10.1126/science.1079666 12522257
9. CL Corless A Schroeder D Griffith, et al. 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 5357 5364 1:CAS:528:DC%2BD2MXpslOrtLY%3D 10.1200/JCO.2005.14.068 15928335
10. NP Agaram GC Wong T Guo, et al. 2008 Novel V600E BRAF mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors Genes, Chromosomes Cancer 47 853 859 1:CAS:528:DC%2BD1cXhtVCrtLrE 10.1002/gcc.20589 18615679
11. A Agaimy LM Terracciano S Dirnhofer, et al. 2009 V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours J Clin Pathol 62 613 616 1:CAS:528: DC%2BD1MXht1agsbjN 10.1136/jcp.2009.064550 19561230
12. CL Corless L McGreevey A Haley, et al. 2002 KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size Am J Pathol 160 1567 1572 1:CAS:528:DC%2BD38XksVKrt7c%3D 12000708
13. K Kawanowa Y Sakuma S Sakurai, et al. 2006 High incidence of microscopic gastrointestinal stromal tumors in the stomach Hum Pathol 37 1527 1535 10.1016/j.humpath.2006.07.002 16996566
14. W El-Rifai M Sarlomo-Rikala LC Andersson, et al. 2000 DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance Cancer Res 60 3899 3903 1:CAS:528:DC%2BD3cXlt1GktLk%3D 10919666
15. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: pathology and prognosis at different sites Semin Diagn Pathol 23 70 83 10.1053/j.semdp.2006. 09.001 17193820
16. JS Gold SM van der Zwan M Gönen, et al. 2007 Outcome of metastatic GIST in the era before tyrosine kinase inhibitors Ann Surg Oncol 14 134 142 10.1245/s10434-006-9177-7 17080234
17. CD Blanke C Rankin GD Demetri, et al. 2008 Phase III randomized, Intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626 632 1:CAS:528: DC%2BD1cXis1alsLs%3D 10.1200/JCO.2007.13.4452 18235122
18. CD Blanke GD Demetri M von Mehren, et al. 2008 Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 620 625 1:CAS:528:DC%2BD1cXis1alsL0%3D 10.1200/JCO.2007.13.4403 18235121
19. P Rutkowski ZI Nowecki M Debiec-Rychter, et al. 2007 Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117 + gastrointestinal stromal tumors (GISTs) J Cancer Res Clin Oncol 133 589 597 1:CAS:528:DC%2BD2sXnsl2gtLY%3D 10.1007/s00432-007-0202-4 17458563
20. MC Heinrich DJ Griffith BJ Druker, et al. 2000 Inhibition of c-kit receptor kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 925 932 1:CAS:528:DC%2BD3cXltlKitLw%3D 10910906
21. H Joensuu PJ Roberts M Sarlomo-Rikala, et al. 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 1:STN:280:DC%2BD3M3gvVekuw%3D%3D 10.1056/NEJM200104053441404 11287975
22. AT Van Oosterom I Judson J Verweij, et al. 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 1421 1423 10.1016/S0140-6736(01)06535-7 11705489
23. GD Demetri M von Mehren CD Blanke, et al. 2002 Efficacy and safety of imatinb mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 1:CAS:528:DC%2BD38XmtV2nt7s%3D 10.1056/NEJMoa020461 12181401
24. J Verweij PG Casali D Kotasek, et al. 2007 Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005 Eur J Cancer 43 974 978 1:CAS:528:DC%2BD2sXjslGnurk%3D 10.1016/j.ejca.2007.01.018 17336514
25. J Verweij A van Oosterom J-Y Blay, et al. 2003 Imatinib mesylate is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft tissue sarcomas that are unselected for molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer 39 2006 2011 1:CAS:528:DC%2BD3sXmvVKgtrc%3D 10.1016/S0959-8049(02)00836-5 12957454
26. J Verweij PG Casali J Zalcberg, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134 1:CAS:528:DC%2BD2cXnvVOiu7o%3D 10.1016/S0140-6736(04)17098- 0 15451219
27. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) 2010 Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients J Clin Oncol 28 1247 1253 10.1200/JCO.2009.24.2099
28. JY Blay A Le Cesne I Ray-Coquard, et al. 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 1107 1113 1:CAS:528:DC%2BD2sXksVyrs7s%3D 10.1200/JCO.2006.09.0183 17369574
29. Adenis A, Cassier PA, Bui BN, et al.(2008) Does interruption of imatinib in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR 14 trial? Proc Am Soc Clin Oncol (abstr 10522)
30. RE Bechtold MYM Chen CA Stanton, et al. 2003 Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec Abdom Imaging 28 808 814 1:STN:280:DC%2BD2c%2Flt1Kisg%3D%3D 10.1007/s00261-003-0021-2 14753595
31. G Antoch J Kanja S Bauer, et al. 2004 Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45 357 365 1:CAS:528:DC%2BD2cXivVCjur0%3D 15001674
32. BL Eisenberg J Harris CD Blanke, et al. 2009 Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor: early results of RTOG 0132/ACRIN 6665 J Surg Oncol 99 42 47 1:CAS:528:DC%2BD1MXhvFCjur0%3D 10.1002/jso.21160 18942073
33. CP Raut M Posner J Desai, et al. 2006 Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 2325 2331 1:CAS:528:DC%2BD28XlvV2ksbw%3D 10.1200/JCO.2005.05.3439 16710031
34. RP DeMatteo RG Maki S Singer, et al. 2007 Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor Ann Surg 245 347 352 10.1097/01.sla.0000236630.93587.59 17435539
35. A Gronchi M Fiore F Miselli, et al. 2007 Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 341 346 10.1097/01.sla.0000242710.36384.1b 17435538
36. MC Heinrich CL Corless CD Blanke, et al. 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 4764 4774 1:CAS:528:DC%2BD28XhtFynsrrN 10.1200/JCO.2006.06.2265 16954519
37. JR Zalcberg J Verweij PG Casali, et al. 2005 Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg Eur J Cancer 41 1751 1757 1:CAS:528:DC%2BD2MXns1Wit7g%3D 10.1016/j.ejca.2005.04.034 16098458
38. GD Demetri AT van Oosterom CR Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial Lancet 368 1329 1338 1:CAS:528:DC%2BD28XhtVOrtL%2FL 10.1016/S0140-6736(06)69446-4 17046465
39. TF Chu MA Rupnick R Kerkela, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2011 2019 1:CAS:528: DC%2BD2sXhsVent7bN 10.1016/S0140-6736(07)61865-0 18083403